ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES

ID#: NCT04503395

Age: 18 years - 66+

Gender: All

Healthy Subjects: No

Study Phase: N/A

Recruitment Status: Recruiting

Start Date: May 21, 2021

End Date: June 01, 2028

Contact Information:
Sarah Litterscheid, PhD
+49 15785319015
Sarah Litterscheid
+49 15785319015
Summary: The aim of this randomized study is to compare the safety and performance of EndoVascular Aneurysm Repair with ESAR using Endurant + Heli-FX™ EndoAnchor™ system and FEVAR using customizable grafts from Cook (Zenith Fenestrated Graft) and Terumo (Fenestrated Anaconda Graft) for the treatment of aortic aneurysms with short aortic neck (4 to 15mm).
Eligibility:

Inclusion Criteria:

- Subject is >18 years old

- Subject is scheduled for primary treatment of the abdominal aortic aneurysm with a non-aneurysmal infrarenal aortic sealing zone proximal to the aneurysm that is sufficiently healthy for a proximal neck length that is at least 4mm and not more than15 mm and has a circumferential minimum sealing zone length of 8 mm

- Subject is not a candidate for safe, effective and durable standard EVAR due to challenging anatomical criteria as confirmed by the Core Lab screening

- Subject is able and willing to comply with the protocol and to adhere to the follow-up requirements.

- Subject has provided written informed consent CT Angiographic Inclusion Criteria

- Subject meets the other anatomical requirements according to the locally applicable Endurant II/IIs stent graft system, Heli-FX EndoAnchor system, Terumo Fenestrated Anaconda (available in EU only) and/or Cook Zenith Fenestrated Graft Instructions for Use

- Proximal neck length of the aorta within 4-15mm and a minimum circumferential sealing zone of 8mm

- Aortic neck diameter from 19 to 31mm

- Infrarenal neck angulation ≤45°

Exclusion Criteria:

- Subject is participating in a concurrent study which may confound study results

- Subject has a life expectancy <2 year

- Subject is female of childbearing potential in whom pregnancy cannot be excluded

- Subject with eGFR <30 mL/min/m2 (KDOQI classification

- exclude class IV and above) and or on dialysis

- Subject with a MI or CVA within 3 months prior to index procedure

- Subject with known Connective Tissue Disease

- Subject has a known hypersensitivity or contraindication to anticoagulants, antiplatelets, or contrast media, which is not amenable to post-treatment

- Subject who has undergone prior endovascular or open surgical treatment for abdominal aortic aneurysm

- Subject requires emergent aneurysm treatment, for example, trauma or rupture

- Subject has a known hypersensitivity or allergies to study device implant material

- Subject has an aneurysm that is:

- Suprarenal, pararenal, or thoracoabdominal

- Mycotic

- Inflammatory

- Pseudoaneurysm

- Subject is presenting with thrombus or calcification of the proximal aneurysm neck: circumferential >50%

- Pre-op stenosis of the renal arteries > 50%

- Subject has active infection or history of COVID-19. History of COVID-19 is defined as availability of positive COVID-19 test with sequelae or hospitalization for treatment of COVID-19.